EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)

医学 耐受性 贝伐单抗 肺癌 无进展生存期 肿瘤科 内科学 癌症研究 T790米 表皮生长因子受体抑制剂 表皮生长因子受体 埃罗替尼 不利影响 吉非替尼 非小细胞肺癌 癌症 化疗 A549电池
作者
Andrés F. Cardona,Camila Ordóñez‐Reyes,Alejandro Ruíz-Patiño,Juan Esteban García-Robledo,L. Zatarain Barron,Gonzalo Recondo,Leonardo Rojas,Luis Corrales,Claudio Martín,Feliciano Barrón,Carolina Sotelo,July Rodríguez,Luisa Ricaurte,Christian Rolfo,Jenny Ávila,D. Mayorga,Pilar Archila,Jorge Otero,Luís Más,Maritza Bermúdez
出处
期刊:JCO precision oncology [Lippincott Williams & Wilkins]
卷期号: (5): 839-848 被引量:6
标识
DOI:10.1200/po.20.00404
摘要

BIM activation is essential for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-triggered apoptosis in EGFR-mutant non-small-cell lung cancer (NSCLC). A deletion in the intron two of the BIM gene results in generation of alternatively spliced isoforms that impairs their apoptotic response to TKIs, conferring the NSCLC cells intrinsic resistance to these medications. Patients with both alterations have poor clinical evolution. The current study aimed to investigate the clinical efficacy and tolerability of EGFR-TKIs plus bevacizumab (Bev) versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations and BIM deletions (BIMdel).A retrospective analysis was conducted. BIMdel was detected using polymerase chain reaction analysis and direct sequencing of DNA. BIM protein expression was investigated by immunohistochemistry, and BIM mRNA levels by reverse transcriptase-polymerase chain reaction. Clinical characteristics, overall survival, progression-free survival (PFS), overall response rate (ORR), and treatment-related adverse events were compared between both groups.Thirty-three patients were included; 15 received EGFR-TKIs, and 18 received EGFR-TKIs plus Bev. The median age was 63 years, with a majority of recruited female patients. All included individuals had an Eastern Cooperative Oncology Group performance score of 2 or less. The addition of Bev resulted in a significantly higher ORR (94.4% v 40%, P > .001). Median PFS was longer with the use of the combination therapy (11.12 v 7.87 months; P = .001). Median overall survival tended to be longer in the EGFR-TKIs plus Bev (30.9 v 25.4 months; P = .06) but failed to reach statistical significance. Response in terms of both partial and complete as well as overall favorably affected PFS.EGFR-TKIs plus Bev conferred a significantly higher ORR and PFS in advanced NSCLC patients with EGFR mutation and BIMdel. Further prospective studies are needed to validate these findings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被拼搏的白玉采纳,获得10
刚刚
Hupdou完成签到,获得积分10
刚刚
1秒前
虎虎发布了新的文献求助10
1秒前
6a完成签到 ,获得积分10
1秒前
1秒前
JamesPei的应助被whisper采纳,获得10
2秒前
我有颗糖发布了新的文献求助10
2秒前
大个的应助被喵喵采纳,获得10
2秒前
车紊发布了新的文献求助10
3秒前
杨凡华发布了新的文献求助10
3秒前
傻傻的起眸完成签到,获得积分10
3秒前
郭佳佳完成签到,获得积分10
4秒前
李李完成签到,获得积分10
4秒前
4秒前
4秒前
自成发布了新的文献求助10
4秒前
huagelihai完成签到,获得积分10
4秒前
4秒前
123发布了新的文献求助10
5秒前
5秒前
5秒前
7秒前
7秒前
可乐发布了新的文献求助10
7秒前
David完成签到,获得积分10
8秒前
8秒前
8秒前
爱笑绿柳完成签到,获得积分10
8秒前
cbs完成签到 ,获得积分10
9秒前
9秒前
能干的绯发布了新的文献求助10
9秒前
书包王发布了新的文献求助10
10秒前
杨凡华完成签到,获得积分10
10秒前
11秒前
科研通AI2S的应助被Shu舒采纳,获得10
11秒前
11秒前
领导范儿的应助被南海神尼采纳,获得10
11秒前
12秒前
共享精神的应助被vv采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181155
求助须知:如何正确求助?哪些是违规求助? 9571140
关于积分的说明 21816740
捐赠科研通 7777528
什么是DOI,文献DOI怎么找? 3433436
关于科研通互助平台的介绍 2557664
邀请新用户注册赠送积分活动 2479482